Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab.

Authors:
Chiang RS; Glover MJ; Khaki AR; Srinivas S.

Journal:
Onco Targets Ther

Publication Year: 2022

DOI:
10.2147/OTT.S369043

PMCID:
PMC9582299

PMID:
36275184

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Onco Targets Ther

Abbreviation: Onco Targets Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Applications of Yttrium-90 (<sup>90</sup>Y) in Hepatocellular Carcinoma.
Jiang Z; Yang F; Wang W. (2024) - Transparency Score: 3/6
Crosstalk Between circRNA and Tumor Microenvironment of Hepatocellular Carcinoma: Mechanism, Functi…
Xie C; Hao X; Yuan H and 3 more (2024) - Transparency Score: 3/6
Prognostic Factors and Construction of Nomogram Prediction Model of Lung Cancer Patients Using Clin…
Zhang Y; Wan W; Shen R and 6 more (2024) - Transparency Score: 3/6
TSC22D2 Regulates ACOT8 to Delay the Malignant Progression of Colorectal Cancer.
Zhou N; Guo C; Du J and 4 more (2024) - Transparency Score: 3/6
Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Directi…
Buller DM; Antony M; Ristau BT. (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure Dr Ali Raza Khaki reports Research collaborations with Tempus Labs and Natera. The authors have no other conflict of interests to declare."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025